Sustained Release Anti-Psychotic Drug Patent Invalid
A long-standing and valuable patent, protecting sustained release versions of a market leading anti-psychotic drug, has been declared invalid due to the absence of any inventive steps in formulation that would not have been ‘obvious’ to a skilled pharmacology team more than 20 years ago.